Overview of a promising new study of venetoclax in patients with CLL
Venetoclax monotherapy for relapsed/refractory multiple myeloma
Triple combination therapies for multiple myeloma (MM) patients
Heinz Ludwig et al.
Results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in CLL
Why drug combinations are the future of treatment in CLL